Which is better, GSK or PME.AX?

On the Buffett-Fit framework, Pro Medicus Limited (PME.AX) currently grades higher than GSK — 78/100 (B grade) vs 58/100 (C). That said, "better" depends on which framework you trust — GSK wins on none; PME.AX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy GSK or PME.AX?

This page is an educational comparison, not investment advice. Both GSK and PME.AX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is GSK better than PME.AX for value investing?

On the Buffett-style value-investing framework, PME.AX currently grades higher — 78/100 vs 58/100, a 20-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between GSK and PME.AX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GSK currently scores 58/100 (C grade); PME.AX scores 78/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GSK or PME.AX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GSK and PME.AX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GSK or PME.AX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GSK and PME.AX both Healthcare stocks?

Yes — both GSK plc (GSK) and Pro Medicus Limited (PME.AX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GSK vs PME.AX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

GSK

GSK$101.7BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$18.81BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

GSK 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

GSK0wins

7winsPME.AX

Warren Buffett

58D

B78

Benjamin Graham

62C

A90

Philip Fisher

66C

A98

Peter Lynch

47D

A100

Joel Greenblatt

35F

B84

Charlie Munger

65C

A91

Terry Smith

63C

A96

Side-by-side metrics

Metric	GSK	PME.AX
Market cap	Winner: $101.7B	$18.81B
P/E (TTM)	Winner: 13.0x	147.6x
EV/EBIT	Winner: 10.9x	106.8x
ROIC (TTM)	13.76%	42.56% Winner
Gross margin	72.74%	99.85% Winner
Net margin	17.78%	54.12% Winner
Revenue CAGR 5y	7.24%	31.61% Winner
EPS CAGR 5y	19.78%	37.34% Winner
Debt / Equity	1.1x	0.0x Winner
Dividend yield	3.56%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GSK leads on

P/E (TTM)13.0xvs 147.6x+91%
EV/EBIT10.9xvs 106.8x+90%
Market cap$101.7Bvs $18.81B+82%

PME.AX leads on

Debt / Equity0.0xvs 1.1x+99%
Revenue CAGR 5y31.61%vs 7.24%+77%
ROIC (TTM)42.56%vs 13.76%+68%
Net margin54.12%vs 17.78%+67%

More like GSK

GSK vs 1681.HK GSK vs SANOFICONR.NS GSK vs SANOFICONR.BO GSK vs CAMX.ST

More like PME.AX

PME.AX vs 1681.HK PME.AX vs SANOFICONR.NS PME.AX vs SANOFICONR.BO PME.AX vs CAMX.ST

Read the full Buffett-Brain analysis for GSK Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

GSK

GSK$101.7BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$18.81BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

GSK 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

GSK0wins

7winsPME.AX

Warren Buffett

58D

B78

Benjamin Graham

62C

A90

Philip Fisher

66C

A98

Peter Lynch

47D

A100

Joel Greenblatt

35F

B84

Charlie Munger

65C

A91

Terry Smith

63C

A96

Side-by-side metrics

Metric	GSK	PME.AX
Market cap	Winner: $101.7B	$18.81B
P/E (TTM)	Winner: 13.0x	147.6x
EV/EBIT	Winner: 10.9x	106.8x
ROIC (TTM)	13.76%	42.56% Winner
Gross margin	72.74%	99.85% Winner
Net margin	17.78%	54.12% Winner
Revenue CAGR 5y	7.24%	31.61% Winner
EPS CAGR 5y	19.78%	37.34% Winner
Debt / Equity	1.1x	0.0x Winner
Dividend yield	3.56%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GSK leads on

P/E (TTM)13.0xvs 147.6x+91%
EV/EBIT10.9xvs 106.8x+90%
Market cap$101.7Bvs $18.81B+82%

PME.AX leads on

Debt / Equity0.0xvs 1.1x+99%
Revenue CAGR 5y31.61%vs 7.24%+77%
ROIC (TTM)42.56%vs 13.76%+68%
Net margin54.12%vs 17.78%+67%

More like GSK

GSK vs 1681.HK GSK vs SANOFICONR.NS GSK vs SANOFICONR.BO GSK vs CAMX.ST

More like PME.AX

PME.AX vs 1681.HK PME.AX vs SANOFICONR.NS PME.AX vs SANOFICONR.BO PME.AX vs CAMX.ST

Read the full Buffett-Brain analysis for GSK Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.